April 12, 2023
IN THIS ISSUE / April 12, 2023
Perioperative imaging for high-stage cutaneous SCC may guide management
DermWorld Insights and Inquiries: Triskaidekaphobia legitimized: Fatal Factor XIII deficiency
Perioperative imaging for high-stage cutaneous SCC may guide management
A retrospective cohort study published in JAAD identified 99 cases of BWH T2b/T3 cutaneous squamous cell carcinoma (cSCC) with imaging related to primary tumor management before or within 30 days of treatment. Overall, 38% of cases had abnormal imaging results. In 30% of cases, imaging-guided management was performed, prompting additional imaging, adjuvant radiation, systemic treatment, or a change in surgical plan. Metastasis was confirmed in 16% of cases. The authors concluded that imaging should be considered during the initial management of high-stage cSCC as it changed management in nearly one-third of the cohort.
Changes to TNM system enhance prognostication for cutaneous cancers. Read more in DermWorld.
DermWorld Insights and Inquiries: Triskaidekaphobia legitimized: Fatal Factor XIII deficiency
essential to review other pertinent issues in this manuscript. Acquired Factor XIII deficiency should be considered in patients with autoimmune diseases presenting with hemorrhagic complications that are otherwise unexplained by standard coagulation studies. Keep reading!
Contact allergens in nail products
Authors of a study published in Contact Dermatitis investigated nickel, cobalt, and chromium release and content of 50 commonly used nail stickers and tips. Eighty-six qualitative spot tests were performed, which found nickel was released in 8.1% of tests before and 11.6% tests after exposure to artificial sweat. Cobalt and chromium spot test results were negative. Inductively coupled plasma-optical mass spectrometry detected nickel, cobalt, and chromium in 11%, 6.3%, and 16.7% of the samples, respectively. Higher detection rates were found in nail tips than in nail stickers.
Are you a rash whisperer? Read more in DermWorld.
Contact allergens in natural skin products – DermWorld Weekly (November 2022)
Share with patients and the public: Skin care advice for 20-somethings
Allergen of the year 2022: Aluminum – DermWorld Insights and Inquiries (June 2022)
DataDerm™: 2022 Annual Report
In 2016, the AAD launched its clinical data registry, DataDerm. The third annual report of DataDerm has recently been published in JAAD. As of Dec. 31, 2021, DataDerm contained data from 13,151,224 unique patients and 46,994,534 unique patient visits. In 2021, 403 practices representing 1,670 clinicians actively participated in the registry. All 834 members that reported MIPS through DataDerm in 2021 avoided the penalty and earned an incentive. As of Dec. 31, 2021, 25 different EHRs have been integrated with DataDerm.
[View a list of EHRs recognized by DataDerm.]
The Academy is working in collaboration with OM1, a real-world outcomes and technology company that serves as the data analytics partner of DataDerm, to enhance our analytics capabilities. Table 6 shows the longitudinal nature of dermatologic care for the following six common dermatologic conditions: acne, alopecia, atopic dermatitis (AD), psoriasis, melanoma, and non-melanoma skin cancer can be viewed. Table 7 documents the number and percentage of patients treated with topical medications only, systemic medications only, or both topical and systemic medications for both AD and psoriasis. Nearly 70% of psoriasis patients were treated with only topical medications and 93% of atopic dermatitis patients were treated with only topical medication.
If you would like to learn more about DataDerm, contact the Academy’s DataDerm team at DataDerm@aad.org.
Drivers of mortality in Merkel cell carcinoma
Authors of a study published in JAAD found that of 9,375 patients diagnosed with Merkel cell carcinoma (MCC), 5,815 died over a median duration of 27 months of follow-up. MCC accounted for just over 40% of the deaths, cardiovascular disease accounted for nearly 20% of the deaths, and other malignancies accounted for 17% of the deaths.
[FDA grants accelerated approval to MCC drug. Read more in DermWorld Weekly.]
Patients who died as a result of CVD were older at the time of diagnosis of MCC compared with those who died from MCC. Patients with MCC were 8.2 times more likely to die from CVD compared with the general population. The authors found that the majority of patients with MCC die due to non-MCC–-related causes, with CVD and other malignancies accounting for most of the cases.
Life-changing advances and a multidisciplinary approach give new hope to patients with Merkel cell carcinoma. Read more in DermWorld.
MCC survival by anatomic site – DermWorld Weekly (June 2021)
Occupational associations of skin cancer – DermWorld (March 2023)
Reporting period deadline extended for COVID relief funds
The Health Resources & Services Administration (HRSA) announced that it is extending the reporting period for Reporting Period 4 of the Provider Relief Funds from March 31 to April 28, 2023, by 11:59 p.m. ET. Providers will have an opportunity to submit a Request to Report Late Due to Extenuating Circumstances if one or more of the extenuating circumstances outlined on the website are applicable.
